GSK-547 free base · Synonyms: GSK'547
GSK547 is a highly selective and potent inhibitor of RIP1.
For research use only. Not for human or veterinary use.
GSK-547 structure
CAS No.: 2226735-55-1
Pack sizes & pricing
Description
GSK547 is a highly selective and potent inhibitor of RIP1.
Biological activity
In Vitro GSK547 (0.1-100000 nM; 24 hours) pretreats L929 cells with recombinant TNFα and zVAD at various doses for 30 min, then cell death is induced with an IC50 of 32 nM after 24 hours. ? GSK547 up-regulates STAT1 signaling in bone marrow-derived macrophages (BMDM). In Vivo GSK547 (GSK′547; RIP1i) robustly targets RIP1 in vivo. RIP1 inhibition results in immunogenic macrophage differentiation in pancreatic cancer, leading to adaptive immune activation and tumor protection for pancreatic ductal adenocarcinoma (PDA). ? GSK547 (100 mg/kg/day; fed via food-based dosing; 15-50 days) reduces tumor burden and extends survival compared with mice treated with controls or Nec-1s.
Identifiers
- SMILES
-
FC1=CC(=CC(F)=C1)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N - InChIKey
-
SJVGFKBLUYAEOK-SFHVURJKSA-N
Specifications
- MW (average)
- 396.3933
- Formula
- C20H18F2N6O
- CAS No.
- 2226735-55-1
- Physical state
- Solid
- Color
- White to off-white
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20℃ 2 years; In solvent -20℃ 1 month;
Solubility
Soluble in DMSO >100 mg/mL
Documents
References
Same target
Search RIP kinaseSame research area
Search Cancer- BP-00006 SLF Exclusive free base · >98%
- BP-00008 NSC-339004 free base · >98%
- BP-00019 SLF-amido-C2-COOH free base · >98%
- BP-00020 PT262 free base · >98%
- BP-00022 Inolitazone free base · >98%
- BP-00024 KX2-361 free base · >98%
- BP-00030 EML4-ALK kinase inhibitor 1 free base · >98%
- BP-00037 SB 328437 free base · >98%